STROMUSC YK11 10mg*100 For Bodybuilding CAS:1370003-76-1

   What is YK11?

    ●Core Identity: YK11 (chemical name: 17β-hydroxy-2α,3α-epithio-17α-methylandrostan-3-one) is a synthetic steroidal molecule. Its primary claimed mechanism is dual-action: acting as a partial agonist of the androgen receptor (AR) and, more significantly, functioning as a potent myostatin inhibitor.

    ●Mechanism Distinction: This myostatin focus is its defining characteristic. Myostatin (Growth Differentiation Factor 8 - GDF-8) is a naturally occurring protein produced by muscle cells. Its biological role is to act as a negative regulator of skeletal muscle growth. It signals muscle cells to stop growing and differentiating once a certain threshold is reached, essentially acting as a "brake" on muscle development.

    ●The Hypothesis: By inhibiting myostatin, YK11 theoretically removes this brake, allowing for potentially unprecedented muscle hypertrophy and hyperplasia (increasing the number of muscle fibers, not just their size). Its partial AR binding may offer some direct anabolic stimulus, but the myostatin inhibition is considered its primary proposed mechanism.

    ●Steroidal Backbone: Unlike non-steroidal SARMs, YK11 possesses a modified steroidal structure. This inherently carries a higher risk of interacting with other steroidal pathways (like estrogen conversion, liver stress) compared to typical SARMs.

    ●Partial Androgen Receptor Agonist: Binds to the AR in muscle and bone tissue, potentially stimulating anabolic pathways like protein synthesis. However, its partiality might imply less potent direct androgenic effects than full agonists like testosterone or DHT derivatives, though this is debated.

    ●Potent Myostatin Inhibitor (Claimed): The core proposed feature. It purportedly binds to and blocks the activin type IIB receptor (ActRIIB), the receptor myostatin uses to signal muscle cells. This blockade prevents the myostatin signal cascade that suppresses muscle growth.

    ●Potential for Hyperplasia: This is arguably the most alluring and speculative feature. While hypertrophy (increasing fiber size) is the primary mechanism of most anabolics, YK11's myostatin inhibition could theoretically stimulate satellite cells to fuse and form entirely new muscle fibers (hyperplasia). Achieving hyperplasia in humans beyond developmental stages is notoriously difficult.

    ●Oral Bioavailability: YK11 is administered orally and is reported to have reasonable bioavailability in its raw form, though specific human data is lacking. Some users experiment with sublingual administration seeking enhanced absorption.

    ●Research Status: Crucially, YK11 remains a research chemical. Its safety and efficacy profile in humans is unknown. All human data is anecdotal, derived from uncontrolled, unsanctioned use within the bodybuilding community. Preclinical studies are limited and primarily in vitro or rodent models.

    ●Primary Goal: Extreme Muscle Growth: Users seek YK11 to push muscle mass gains beyond perceived natural limits or what's achievable with traditional steroids/SARMs alone, specifically targeting the removal of the myostatin "brake."

    ●Breaking Plateaus: Employed during periods of stalled progress, aiming to overcome genetic limitations imposed by naturally high myostatin levels.

    ●Lean Mass Accretion: Anecdotal reports often emphasize gaining lean, dense muscle with minimal water retention compared to some wet steroids, attributed to its non-aromatizing nature and myostatin focus.

    ●Potential Strength Increases: Significant muscle growth often correlates with strength gains. Some users report disproportionate strength increases, potentially linked to neural adaptations or specific muscle fiber changes.

    ●Stacking Synergy: Frequently stacked with other compounds:

    ○SARMs (Ostarine, Ligandrol, RAD140): To provide a stronger baseline anabolic stimulus via AR activation.

    ○Testosterone/Base Hormone: To ensure sufficient androgen levels for bodily functions and prevent suppression symptoms (YK11 is suppressive).

    ○Other Myostatin Inhibitors (Follistatin, ACE-031 analogs - rare/research): Attempting synergistic myostatin blockade (highly speculative and risky).

    ○Peptides (e.g., IGF-1 LR3, HGH Fragments): Targeting complementary growth pathways.

    ●Accelerated Muscle Growth: Potential for rapid gains in lean muscle mass, surpassing typical rates.

    ●Enhanced Muscle Density and Hardness: Often described as producing "granite-like" muscle quality, likely due to the myostatin inhibition focus and lack of estrogenic water.

    ●Increased Strength: Correlated with significant muscle gain.

    ●Reduced Fat Gain: Anecdotal reports suggest it can be used during lean bulking phases with minimal fat accumulation, possibly related to metabolic effects or the nature of the gained tissue.

    ●Non-Aromatizing: Does not convert to estrogen (estradiol), eliminating risks of gynecomastia or significant water retention directly caused by estrogen. However, suppression of natural testosterone production can still lead to low estrogen symptoms.

    ●Potential for Hyperplasia: The tantalizing, yet unproven in humans, possibility of increasing muscle fiber number.

    ●Significant Uncertainty: Human dosing is entirely extrapolated from rodent studies and anecdotal bro-science. There is no established safe or effective human dose.

    ●Common Anecdotal Range: 5mg to 15mg per day, typically split into two doses (e.g., morning and evening).

    ●Sublingual Experimentation: Some users dissolve the powder under the tongue for several minutes before swallowing, theorizing faster absorption and potentially higher bioavailability by bypassing first-pass liver metabolism. Evidence for superiority over oral ingestion is lacking.

    ●Cycle Length: Anecdotal cycles typically last 6-8 weeks. Longer durations increase the risk of significant liver strain and profound suppression. Due to its steroidal nature and hepatotoxicity risk, longer cycles are strongly discouraged.

    ●Critical Consideration: Starting at the lowest possible dose (e.g., 5mg/day) is highly recommended to assess individual tolerance. Liver support supplements (NAC, TUDCA, Milk Thistle) are considered essential.

    ●Monocycle (Rare): Using YK11 alone is uncommon due to its suppression and the desire for more pronounced effects. A testosterone base is almost always recommended.

    ●Typical Stack Example (8 Weeks):

    ○Weeks 1-8: Testosterone Enanthate/Cypionate (250-500mg/week) OR a SARM like RAD140 (10-20mg/day) + YK11 (5-10mg/day split dose)

    ○Crucially: Include liver support throughout.

    ●Advanced Stack Example (Riskier):

    ○Weeks 1-8: Testosterone (300-500mg/week) + YK11 (10mg/day) + RAD140 (20mg/day) or Ostarine (25mg/day)

    ○Intense hepatotoxicity and suppression monitoring essential.

    ●Post Cycle Therapy (PCT): Mandatory after any YK11 cycle (see section 7).

    ●Estimated Range: Based on its steroidal structure and anecdotal reporting, YK11's half-life is generally estimated to be between 12 to 24 hours.

    ●Implications: This relatively short half-life necessitates split daily dosing (e.g., every 12 hours) to maintain stable blood levels and consistent myostatin inhibition. Taking it once daily would lead to significant peaks and troughs.

    ●Profound Suppression: YK11, despite being a partial AR agonist, is highly suppressive of the hypothalamic-pituitary-testicular axis (HPTA). It significantly lowers natural testosterone production. This suppression is comparable to or potentially greater than many traditional steroids due to its steroidal nature and impact on hormonal pathways.

    ●PCT Imperative: A structured PCT is non-negotiable to restore natural hormone production after a YK11 cycle. Skipping PCT risks prolonged low testosterone, leading to muscle loss, fat gain, low libido, depression, and fatigue.

    ●Typical PCT Protocol (4-6 Weeks): Begins after YK11 and any esters (like Testosterone Enanthate) have sufficiently cleared the system (usually 1-2 weeks after last YK11 dose if no esterified test; wait for ester half-life if using injectable test).

    ○SERM Core:

    ◇Weeks 1-4: Clomiphene Citrate (Clomid) 25-50mg per day OR Tamoxifen Citrate (Nolvadex) 20-40mg per day.

    ◇Weeks 1-2 (Optional Boost): Often starts with a slightly higher dose (e.g., Clomid 50mg, Nolvadex 40mg).

    ○Supporting Compounds (Commonly Used):

    ◇Natural Test Boosters: May offer marginal support (e.g., D-Aspartic Acid, Ashwagandha, Vitamin D3, Zinc).

    ◇Aromatase Inhibitor (AI): Only if symptoms of high estrogen arise during PCT (due to the rapid rise of testosterone without corresponding estradiol production initially). Not routinely needed. Example: Anastrozole 0.25mg EOD if high E2 symptoms appear.

    ●Blood Work: The gold standard. Pre-cycle, mid-cycle (if long), and post-PCT blood tests (Total Testosterone, Free Testosterone, LH, FSH, Estradiol, Liver Enzymes - ALT/AST, Lipids) are strongly recommended to gauge suppression severity and PCT effectiveness.

    ●Research Chemical Status: YK11 is NOT approved for human consumption. It is sold strictly for laboratory research. Human safety is unproven.

    ●Liver Toxicity (Hepatotoxicity): Its steroidal structure poses a significant risk of liver damage, including elevated liver enzymes and potentially hepatitis. Liver support is essential, but not foolproof. Regular liver enzyme monitoring is critical.

    ●Cardiovascular Risks: Potential negative impact on cholesterol profiles (lowering HDL, raising LDL) is likely, increasing cardiovascular risk. Lipid monitoring is important.

    ●Suppression: Severe and rapid suppression of natural testosterone production, leading to hypogonadal symptoms if not managed with a base hormone or proper PCT.

    ●Unknown Long-Term Effects: The consequences of long-term myostatin inhibition in humans are completely unknown. Potential risks could include tendon weakness, heart muscle issues (myostatin is expressed in the heart), or other unforeseen pathologies.

    ●Purity & Legality: The research chemical market is unregulated. Product purity, dosage accuracy, and even identity are major concerns. Possession may be illegal depending on jurisdiction.

    ●Lack of Human Evidence: All purported benefits and dosing protocols are based on extremely limited animal data and uncontrolled, biased human anecdotes. The risk-to-benefit ratio is unknown and potentially unfavorable.

Brand	STROMUSC
Trade names	YK11; (17α,20E)-17,20-diene-21-carboxylic acid methyl ester
CAS	1370003-76-1
Molar mass	430.541
Formula	C25H34O6
Purity	Above 98%
Apprarance	10mg*100

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

                                   

 

    YK11 represents a fascinating but highly speculative and risky frontier in bodybuilding enhancement. Its proposed mechanism – targeting the myostatin "brake" – offers the alluring potential for unprecedented muscle growth, possibly including hyperplasia. Anecdotal reports describe impressive gains in lean mass and density. However, these potential benefits are overshadowed by significant dangers: unproven human safety, substantial liver toxicity risk, profound hormonal suppression, cardiovascular concerns, and complete lack of regulatory oversight or quality control. It is unequivocally a research chemical, not a supplement.

    Any individual considering YK11 must approach it with extreme caution, prioritizing comprehensive blood work, liver support, a testosterone base or meticulous PCT, and a full understanding of the potentially severe health risks involved. The pursuit of extreme muscle growth via YK11 carries inherent dangers that far outweigh the established safety profiles (though still risky) of traditional AAS or SARMs. Extreme discretion and medical monitoring are paramount.

Hot Tags: stromusc yk11 10mg*100 for bodybuilding cas:1370003-76-1, China stromusc yk11 10mg*100 for bodybuilding cas:1370003-76-1 manufacturers, suppliers, factory